Catheter Precision Completes Acquisition of Flyte
Catheter Precision(VTAK) announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte from Creatd, Inc. (CRTD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure, and scalable fleet economics. Flyte operates under FAA 14 CFR Part 135 certification, deploying Cirrus Vision Jets across high-frequency, short-haul regional routes where commercial airline capacity remains constrained or does not exist. The business currently generates revenue through the operation of aircraft equipped with advanced integrated safety systems, including whole-aircraft parachute technology and Safe Return autonomous landing capability. With full ownership now complete, all Flyte operations, assets, and economics are fully consolidated within VTAK, providing direct exposure to operating performance and long-term equity value creation. Going forward, Flyte's financial results will be consolidated into VTAK's financial statements.
Trade with 70% Backtested Accuracy
Analyst Views on VTAK
About VTAK
About the author


- Flight Capacity Increase: Flyte announced an increase in flight capacity following the shutdown of Spirit Airlines, planning to expand its Vision Jet fleet to meet rising domestic route demand, which is expected to enhance service availability and improve customer experience.
- Hiring Initiative Launched: Flyte has initiated a hiring program targeting pilots and aviation professionals affected by Spirit Airlines' exit, providing a structured onboarding and training pipeline to help industry talent transition smoothly into Flyte's operations.
- Market Response Analysis: The shutdown of Spirit Airlines has impacted approximately 17,000 employees, and Flyte anticipates attracting some displaced customers seeking short-haul travel alternatives, which may lead to higher fares and increased interest in alternative travel options.
- Strategic Expansion Direction: Flyte's expansion plans align with its existing growth strategy, aiming to optimize regional route coverage and enhance fleet utilization, thereby solidifying its competitive position in high-demand short-haul markets.

- Airline Shutdown: CATHETER PRECISION INC - SPIRIT AIRLINES has announced a shutdown affecting its operations.
- Employee Impact: The shutdown will impact 17,000 employees, including over 2,400 pilots.

Flight Capacity Increase: Airlines are increasing their flight capacity to accommodate rising travel demand.
Shifting Travel Trends: The launch of new initiatives by airlines reflects changing patterns in U.S. air travel.
- Market Structural Shift: As airlines cut short-haul routes due to rising fuel costs and operational constraints, Flyte is accelerating its expansion in short-haul markets, anticipating a multi-billion-dollar opportunity, particularly in critical travel corridors in the Northeast where demand remains strong.
- High-Frequency Service Advantage: Flyte utilizes the Cirrus Vision Jet to deliver high-frequency short-haul services, directly addressing the markets vacated by commercial airlines, optimizing flight frequency and scheduling flexibility to meet the needs of high-income and business travelers seeking rapid transit.
- Enhanced Economic Efficiency: Flyte's operational model reduces dependence on congested hub infrastructure, providing higher aircraft utilization and significantly lower fuel consumption per trip, ensuring competitiveness even as airlines raise ticket prices in response to increased operating costs.
- Continued Growth Expectations: As airlines continue to optimize for profitability, Flyte expects the reduction in short-haul service to persist, further enhancing its pricing power and market share in underserved regions.
- Significant Revenue Growth: Catheter Precision reported Q4 revenue of $0.24 million, reflecting a robust 60% year-over-year increase, indicating strong market performance and growth potential.
- Improved Net Loss: The company recorded a net loss of $5.3 million, an improvement from $5.6 million in 2024, suggesting enhanced cost control and operational efficiency.
- Equity Transaction Completed: Creatd sold its remaining stake in Fly Flyte to Catheter Precision for approximately $12 million in cash and equity, which will strengthen the latter's market position and resource integration capabilities.
- Enhanced Financial Transparency: Catheter Precision provided detailed financial information, boosting investor confidence in the company's future prospects and offering clearer decision-making insights for potential investors.
- Financing Amount: Catheter Precision, Inc. announced it has secured up to $88 million in new institutional financing aimed at accelerating growth, simplifying its balance sheet, and expanding its aviation and medical device operations, reflecting strong confidence in future development.
- Aviation Expansion: The newly acquired capital will be utilized by its aviation subsidiary, Flyte, Inc., to expand its fleet, acquire additional aircraft, and enter new regional markets, thereby enhancing the company's competitiveness in the air transport sector.
- Commitment to Medical Devices: In addition to aviation, Catheter Precision reaffirmed its commitment to its cardiac arrhythmia medical device business, with the financing providing resources to strengthen both divisions and enhance its capabilities in healthcare innovation.
- Stock Split Impact: The company executed a 1-for-19 reverse stock split on August 15, 2025, and although the stock is down 14.04% in pre-market trading, it still reflects a positive market response to the financing announcement.







